GENE THERAPY CLINICAL TRIALS

Cristina Sampaio MD, PhD
Chief Medical Officer
Professor Clinical Pharmacology (ULisboa, PT)

April, 2019

CRISTINA.SAMPAIO@CHDIFOUNDATION.ORG
SUMMARY

- GENE THERAPY UNIQUENESS
  INVASIVENESS (in vivo) or COMPLEXITY (ex-vivo)
  DURABILITY

- PLACEBO CONTROL IN GTCT.

- PATIENT RECRUITMENT
  AVOIDING "THERAPEUTIC MISCONCEPTION"
GENE THERAPY DEFINITIONS

EMA
Gene therapy medicinal products generally consist of a vector or delivery formulation/system containing a genetic construct engineered to express a specific transgene (therapeutic sequence) for the regulation, repair, replacement, addition or deletion of a genetic sequence. By using such gene therapy constructs in vivo, genetic regulation or genetic modification of somatic cells can be achieve in situ. The same gene therapy vector can be used ex vivo for the manufacture of genetically modified cells.

FDA
GTMP Is a product that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells in vivo or transferred to cells ex vivo prior to administration to the recipient.
GT FOR CNS DISEASES - INVASIVE/COMPLEX ADMINISTRATION

Piguet F et al; 2017
Gene Therapy Clinical Trials – Uniqueness

<table>
<thead>
<tr>
<th>Trait</th>
<th>Description</th>
</tr>
</thead>
</table>
| Gene therapy Targets          | • Adm. Invasive
                                 | • Uncertain Long-term                            |
| High Unmet Need               | • Urgency
                                 | • Exceptionalism                                 |
| Rare Disease                  | • Recruitment constrained                       |
| Very Rare Disease             | • Standard trial design impossible               |
HUNTINGTON'S DISEASE 1ST GTCT START ANNOUNCED IN JAN 2019.

- AMT-130 COMPRISSES A RECOMBINANT AAV5 VECTOR CARRYING A DNA CASSETTE ENCODING A MICRORNA THAT NON-SELECTIVELY LOWERS OR KNOCKS-DOWN HUMAN HUNTINGTIN PROTEIN IN HUNTINGTON'S DISEASE PATIENTS.
IMPORTANT CONSTRAINTS IN GTCT IN NEURODEGENERATIVE DISEASES

EVEN FOR NON-RARE DISEASES THE NUMBER OF POTENTIAL PARTICIPANTS IS SMALL.

The invasiveness/complexity of administration makes scalability of procedures difficult.

PARTICIPANTS
Too high expectations
Too much progressed

PLACEBO/ SHAM/DUMB INTERVENTION ARE COMPLEX

Logistics and Practice difficult to implement.

OUTCOMES
Timeline for clinical readout is long.
Paucity of “reasonably like” surrogates.
Monitoring of Gene expression in the target organ/ROI limited.
SOLUTIONS FOR GTCT IN NEURODEGENERATIVE DISEASES

“Traditional” therapies set for incremental improvements

PERSECUTION OF LARGE EFFECT SIZES IN SOME CASES CURATIVE EFFECT.

LONG DURABILITY OF EFFECT, EVENTUALLY LIFE LONG.

RISK MITIGATION

Augmented Information need before trial compared to “traditional” therapies.

“Traditional” therapies last for the duration of the administration.
GTCT in NDD are typically small in size and complex however a placebo/sham/dumb arm is of critical importance to secure blinding.

- Focus on Safety: Avoids safety under or over reporting
- Allows Balanced Interpretation of Biomarker and Early Efficacy Data
- Helps manage participant expectations
Participants high expectations may be consequence of “therapeutic misconception.”

- Therapeutic misconception exists when individuals do not understand that the defining purpose of clinical research is to produce generalizable knowledge, regardless of whether the subjects enrolled in the trial may potentially benefit from the intervention under study or from other aspects of the clinical trial.
Reducing therapeutic misconception: A randomized intervention trial in hypothetical clinical trials

Paul P. Christopher¹*, Paul S. Appelbaum², Debbie Truong³, Karen Albert³, Louise Maranda⁴, Charles Lidz³

1 Department of Psychiatry & Human Behavior, Alpert Medical School, Brown University, Providence, RI, United States of America, 2 Division of Law, Ethics, and Psychiatry, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, United States of America, 3 Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, United States of America, 4 Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States of America

Fig 2. Group differences in therapeutic misconception scores by educational level.
TAKE HOME MESSAGE

• Standards of evidence for Gene Therapy must guarantee proof of efficacy and solid safety data.

• GTCT will necessarily be smaller than trials for traditional therapies because of scalability issues.
  • GTCT major advantage is the potential large effect sizes of the therapeutic benefit.

• Management of the expectations both for participants and health professionals (and media) is critical.